1. A Belgian multicentre study of fluvoxamine in depressive outpatients.
- Author
-
Brasseur R, Van Moffaert M, Mesotten F, Ansseau M, Uytdenhoef P, and Bartholome F
- Subjects
- Adult, Ambulatory Care, Antidepressive Agents administration & dosage, Depressive Disorder diagnosis, Female, Fluvoxamine, Humans, Male, Oximes administration & dosage, Psychiatric Status Rating Scales, Antidepressive Agents therapeutic use, Depressive Disorder drug therapy, Oximes therapeutic use
- Abstract
Fluvoxamine, a new antidepressant that specifically inhibits serotonin reuptake, was studied in 272 outpatients in a six-week multicentre trial in Belgium. On the Hamilton Depression Scale, the mean score dropped from 25.2 to 8 after six weeks (p less than 0.00001). The Clinical Global Impression scores showed similar evolution. Fluvoxamine is a real antidepressant with a marked effect on mood. Its effective dosage is 100 mg to 200 mg/day. Its tolerance, notably at the cardiovascular level, is excellent.
- Published
- 1985